Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background And Objectives: Recently, reduction of transcallosal inhibition by contralateral navigated repetitive transcranial magnetic stimulation (nrTMS) improved neurorehabilitation of glioma patients with new postoperative paresis. This multicentric study examines the effect of postoperative nrTMS in brain tumor patients to treat surgery-related upper extremity paresis.
Methods: This is a secondary analysis of two randomized and three one-arm studies in brain tumor patients with new/progressive postoperative paresis. Patients underwent either low frequency contralesional nrTMS or sham stimulation followed by physiotherapy. Outcome was assessed on postoperative day 1, 7, and after 3 months using British Medical Research Council score (BMRC), Fugl-Meyer assessment (FMA), Karnofsky Performance Scale (KPS) and National Institutes of Health Stroke Scale (NIHSS).
Results: A total of 135 patients (mean age of 53.8 years, 60 women) were included, of whom 51 patients were treated in RCTs (30 treatment group, 21 sham group) and 84 in prospective, single-arm studies. Linear mixed models showed an advantage for the treatment group for the BMRC (7 days: OR 3.28; 95%CI: 1.08-9.99; 3 months: OR 2.03, 95%CI: 0.65-6.39) and KPS (7 days: mean difference (MD) 11, 95%CI: 2-19; 3 months: MD 11, 95%CI: 2-20), less pronounced for the FMA (7 days: MD 0.28, 95%CI: -0.34-0.9; 3 months: MD 0.14, 95%CI: -0.52-0.81). A stronger treatment effect was evident with proven ischemia on the postoperative MRI. To observe an improvement by at least one grade at 3 months, the number needed to treat (NNT) for the entire cohort is 4 (BMRC) and 3 patients (KPS), respectively.
Conclusion: Our multicenter data confirm the positive treatment effect of nrTMS to reduce transcallosal inhibition with a considerably low NNT - especially if caused by ischemia.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11937064 | PMC |
| http://dx.doi.org/10.1007/s11060-024-04931-9 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Preventing Glioblastoma Relapse by Igniting Innate Immunity through Mitochondrial Stress in the Surgical Cavity.
Adv Mater
September 2025
Department of Neurosurgery, Qilu Hospital and Shandong Key Laboratory of Brain Health and Function Remodeling, Institute of Brain and Brain-Inspired Science, Jinan Microecological Biomedicine Shandong Laboratory, Cheeloo College of Medicine, Shandong University, 107 Wenhua Xi Road, Jinan, Shandong,
Innate immunity is crucial in orchestrating the brain immune response, however, glioblastoma multiforme (GBM) has evolved sophisticated mechanisms to evade innate immune surveillance, posing significant challenges for current immunotherapies. Here, a therapeutic strategy is reported that aims at reactivating innate immune responses in GBM via targeted induction of mitochondrial stress, thereby enhancing tumor immunogenicity. Specifically, innate immune-stimulating nanoparticles (INSTNA) are developed, encapsulating positively charged iridium-based complexes (Ir-mito) and small interfering RNA against Methylation-Controlled J protein (si-MCJ) to attenuate mitochondrial respiration.
View Article and Find Full Text PDFAdvancing Targeted Drug Delivery in Glioblastoma Multiforme Through Biomimetic Nanomedicine Using 3D Tumor-On-a-Chip Model.
Adv Healthc Mater
September 2025
School of Biological and Health Systems Engineering (SBHSE), Arizona State University, Tempe, AZ, 85287, USA.
The prognosis of glioblastoma multiforme (GBM) remains dismal, despite standard treatment regimens. A key challenge in treating GBM is the persistence of glioma stem cells (GSCs) within the perivascular niche (PVN) - a protective tumor microenvironment (TME) that is often associated with inadequate drug penetration. Current preclinical models do not capture complexity of the human TME, particularly the vasculature and niche-specific interactions that drive GBM progression.
View Article and Find Full Text PDFLazertinib: A Cardio-Safer Alternative to Osimertinib for Epidermal Growth Factor Receptor L858R/T790M Double-Mutant Tyrosine Kinase Resistant Non-Small Cell Lung Cancer.
Drug Dev Res
September 2025
R. C. Patel Institute of Pharmaceutical Education and Research, Shirpur, Maharashtra, India.
Non-small cell lung cancer (NSCLC) remains a leading cause of cancer-related mortality, with "epidermal growth factor receptor (EGFR)" mutations playing a pivotal role in tumor progression and carcinogenesis. "Third-generation epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs)," such as Osimertinib, have significantly improved treatment outcomes by overcoming resistance mechanisms like the T790M mutation. However, Osimertinib's clinical application is limited by cardiotoxicity concerns, necessitating safer alternatives.
View Article and Find Full Text PDFRemote Ischemic Conditioning Attenuates Apoptosis, the Inflammatory Response, and Reperfusion Injury in Ischemic-Stroke Model Rats via the ELA-Apelin-APJ System.
J Integr Neurosci
August 2025
Department of Neurology, Peking University First Hospital Taiyuan Hospital, 030000 Taiyuan, Shanxi, China.
Background: Remote ischemic conditioning (RIC), a novel neuroprotective therapy, has broad potential for reducing the occurrence and recurrence of cerebrovascular events, yet its mechanisms are not incompletely understood. The aim of this study is to investigate whether RIC alleviates apoptosis, inflammation, and reperfusion injury in rat models of ischemic stroke by regulating the Elabela (ELA)-apelin-Apelin receptor (APJ) system.
Methods: We established a rat model of middle cerebral artery occlusion (MCAO) with ischemia-reperfusion injury, and RIC was administered twice daily for 3 days post-MCAO.
Stachydrine Alleviates Sepsis-Induced Cardiomyopathy by Inhibiting Ferroptosis via Regulating SIRT1/GPX4 Pathway.
Dose Response
September 2025
Department of Interventional Radiology, The Second People's Hospital of Nantong, Nantong, Jiangsu Province, China.
Objectives: This study investigated the cardioprotective effects of stachydrine (STA) in lipopolysaccharide (LPS)-induced septic mice and H9c2 cardiomyocytes, focusing on its anti-apoptotic, anti-inflammatory, and anti-ferroptotic actions.
Methods: We established an LPS-induced sepsis model in mice and an LPS-stimulated H9c2 cardiomyocyte model in vitro.
Results: STA markedly reduced LPS-induced myocardial apoptosis, as demonstrated by decreased TUNEL-positive cells, and attenuated the elevation of serum cardiac injury markers, including creatine kinase-MB (CK-MB), lactate dehydrogenase (LDH), brain natriuretic peptide (BNP), cardiac troponin I (cTnI), and cardiac troponin T (cTnT) levels.